ライフサイエンスコーパス: protein synthesis inhibitor

1 osynthesis inhibitor) and chloramphenicol (a protein synthesis inhibitor).

2 h, which was unaffected by pretreatment with protein synthesis inhibitor.

3 protein kinase II (CaMKII) inhibitors and a protein synthesis inhibitor.

4 triggers p100 processing in the presence of protein synthesis inhibitor.

5 Here, we demonstrate that mefloquine is a protein synthesis inhibitor.

6 is blocked by the presence of anisomycin, a protein synthesis inhibitor.

7 N varicosities were blocked by anisomycin, a protein synthesis inhibitor.

8 rin gene expression, even in the presence of protein synthesis inhibitor.

9 by measuring the coentry of alpha-sarcin, a protein synthesis inhibitor.

10 nfections are performed in the presence of a protein synthesis inhibitor.

11 erm treatment with lincomycin, a chloroplast protein synthesis inhibitor.

12 s venezuelae, represent minimalist macrolide protein synthesis inhibitors.

13 s can be directly modulated by commonly used protein synthesis inhibitors.

14 ith cell wall active antibiotics rather than protein synthesis inhibitors.

15 we explored the effect of several eukaryotic protein synthesis inhibitors.

16 epatocytes within 24 hours in the absence of protein synthesis inhibitors.

17 ive-strand RNAs in the presence of different protein synthesis inhibitors.

18 sensitive than wild-type strains to certain protein synthesis inhibitors.

19 LTD has a late phase that may be blocked by protein synthesis inhibitors.

20 EC) produces Shiga-like toxins (SLT), potent protein synthesis inhibitors.

21 nocodazole-treated cells in the presence of protein synthesis inhibitors.

22 polymerization were completely suppressed by protein synthesis inhibitors.

23 antly affect ongoing P-LTF in the absence of protein synthesis inhibitors.

24 comprise an important class of antibacterial protein synthesis inhibitors.

25 pressing P-LTF in the absence or presence of protein synthesis inhibitors.

26 mpounds, including 5a and 5k, seem to act as protein synthesis inhibitors.

27 me serotypes of Escherichia coli, are potent protein synthesis inhibitors.

28 d when hippocampal neurons were treated with protein synthesis inhibitors.

29 glucocorticoids, microtubule inhibitors, and protein synthesis inhibitors.

30 esia vary substantially after treatment with protein synthesis inhibitors.

31 xamined this hypothesis by local infusion of protein-synthesis inhibitor after devaluation of a food

32 Genomic modulators including a protein synthesis inhibitor, an RNA synthesis inhibitor,

33 This effect occurred in the presence of a protein synthesis inhibitor and also in the absence of m

34 ein kinase inhibitor staurosporine, with the protein synthesis inhibitor and protein kinase activator

35 Stxs are potent protein synthesis inhibitors and are the primary virulen

36 AR1 or LTV1 are hypersensitive to particular protein synthesis inhibitors and exhibit aberrant polyso

37 hepatocyte cultures using a broader array of protein synthesis inhibitors and experimental end points

38 g sensitivities to low temperatures, certain protein synthesis inhibitors and high osmolarity.

39 transcription factors, apoptosis regulators, protein synthesis inhibitors and protein degradation fac

40 of transcription, homoharringtonine (HHT), a protein synthesis inhibitor, and imatinib were used sing

41 We found that both cycloheximide, a general protein synthesis inhibitor, and rapamycin, a selective

42 nd GABAB receptors, occur in the presence of protein synthesis inhibitors, and are not influenced by

43 stimuli such as heat shock, UV irradiation, protein synthesis inhibitors, and conditions that elevat

44 his factor, that persists in the presence of protein synthesis inhibitors, and that is therefore medi

45 h a specific context, and the ability of the protein synthesis inhibitor anisomycin administered foll

46 Biedenkapp and J. W. Rudy reported that the protein synthesis inhibitor anisomycin administered into

47 strate that intrahippocampal infusion of the protein synthesis inhibitor anisomycin disrupts both the

48 c or intra-hippocampal administration of the protein synthesis inhibitor anisomycin generally leads t

49 at the impairments in behavior caused by the protein synthesis inhibitor anisomycin given after retri

50 The presence of the protein synthesis inhibitor anisomycin had no effect on

51 mpus 48 h after contextual training with the protein synthesis inhibitor anisomycin impaired memory p

52 Infusion of the protein synthesis inhibitor anisomycin into the LBA shor

53 The protein synthesis inhibitor anisomycin was administered

54 ependent LTD in AS mice was sensitive to the protein synthesis inhibitor anisomycin, and relied on th

55 ion training, followed by treatment with the protein synthesis inhibitor anisomycin, LTS was disrupte

56 ppocampal infusions of vehicle (VEH), of the protein synthesis inhibitor anisomycin, of the D1/D5 dop

57 Both responses were blocked by the protein synthesis inhibitor anisomycin.

58 nosylbenzimidazole (DRB), or infusion of the protein synthesis inhibitor anisomycin.

59 of rapamycin inhibitor temsirolimus and the protein synthesis inhibitor anisomycin.

60 gen peroxide, menadione, heat shock, and the protein synthesis inhibitor anisomycin.

61 e inhibited period was also inhibited by the protein synthesis inhibitor anisomycin.

62 In contrast, the protein synthesis inhibitors anisomycin and puromycin di

63 nction with social support is blocked by the protein synthesis inhibitors anisomycin and rapamycin an

64 s effect is antagonized by administration of protein synthesis inhibitors anisomycin and rapamycin in

65 h were prevented by local application of the protein synthesis inhibitors anisomycin or rapamycin.

66 + MPEP) and their induction was prevented by protein synthesis inhibitor (anisomycin).

67 a transcription inhibitor (actinomycin D) or protein synthesis inhibitors (anisomycin or cycloheximid

68 Animals treated with the protein synthesis inhibitor, anisomycin, into either the

69 Infusions of the protein synthesis inhibitor, anisomycin, prior to defeat

70 eam cellular activation was prevented when a protein synthesis inhibitor, anisomycin, was administere

71 ion, which was inhibited by intrahippocampal protein synthesis inhibitor anisomysin, D1/D5 dopaminerd

72 Protein synthesis inhibitor antibiotics are widely used

73 lts suggest that (1) the amnestic effects of protein synthesis inhibitors are confounded by neural si

74 signaling is delayed and can be inhibited by protein synthesis inhibitor as well as why most classica

75 the data identify microtubule inhibitors and protein synthesis inhibitors as modulators of PGC-1alpha

76 actinomycin D (Act D, 20 micromol/L; n=6), a protein synthesis inhibitor at the transcriptional level

77 d with cycloheximide (CHx, 10 micromol/L), a protein synthesis inhibitor at the translational level,

78 ps significantly with that of the well-known protein synthesis inhibitor balsticidin S.

79 Protein synthesis inhibitors block mossy fiber(MF) LTP m

80 Protein synthesis inhibitors block the maintenance of NM

81 RNA synthesis inhibitor) or cycloheximide (a protein synthesis inhibitor) blocked ganglionic movement

82 Bath application of emetine, a protein synthesis inhibitor, blocked eCB-LTD after affer

83 hrine-deprived conditions in the presence of protein synthesis inhibitor, both the IP3 response and t

84 not only be a function of hygromycin B as a protein synthesis inhibitor but also possibly related to

85 Restoration occurred in the presence of a protein synthesis inhibitor but not after a transcriptio

86 lic inhibitors revealed that cycloheximide a protein synthesis inhibitor, but not phosphonoacetic aci

87 mulation was insensitive to cycloheximide, a protein synthesis inhibitor, but was completely inhibite

88 lease was not diminished by transcription or protein synthesis inhibitors, but was suppressed by bref

89 A brief treatment of the cells with a protein synthesis inhibitor can abolish okadaic acid-ind

90 owever, old memories that are insensitive to protein synthesis inhibitors can become vulnerable if th

91 d by the production of new proteins, because protein synthesis inhibitors can block retrieval of rece

92 e resulting compendium revealed, first, that protein synthesis inhibitors can decouple coordination o

93 nse was cycloheximide-sensitive, because the protein synthesis inhibitor caused a GC-dependent superi

94 lls expressing the transfected TRH receptor, protein synthesis inhibitors caused translocation of int

95 Treatment of E. coli cells with the protein synthesis inhibitor chloramphenicol abolished re

96 The protein synthesis inhibitor chloramphenicol prevents the

97 Pretreatment with protein synthesis inhibitor (CHX), proteasome inhibitor

98 ell-wall-active antibiotic ampicillin or the protein synthesis inhibitor clindamycin or azithromycin.

99 We found that addition of the protein synthesis inhibitor clindamycin to S. aureus LAC

100 occurs in cells that have been treated with protein synthesis inhibitors, consistent with a displace

101 Here, we report that specific protein synthesis inhibitors could either significantly

102 anscription inhibitor actinomycin D, and the protein synthesis inhibitor cyclohexamide suggest that M

103 The eukaryotic protein synthesis inhibitor cycloheximid has been used b

104 bitor actinomycin-D (0.5 microg ml(-1)), the protein synthesis inhibitor cycloheximide (1 microg ml(-

105 e GR antagonist RU-486 (1-10 microM), or the protein synthesis inhibitor cycloheximide (1 microM) fai

106 ect, HCjE cells were treated with RA and the protein synthesis inhibitor cycloheximide (1.0 microg/mL

107 llowing harmful ischemia were blocked by the protein synthesis inhibitor cycloheximide (1.0 muM), a k

108 he generation of IL-8 during chemotaxis, the protein synthesis inhibitor cycloheximide (10 microg/ml)

109 The protein synthesis inhibitor cycloheximide (10 microg/ml)

110 ycin was verified using a single dose of the protein synthesis inhibitor cycloheximide (40 nmol).

111 nt cells and sensitivity was restored by the protein synthesis inhibitor cycloheximide (CHX) and the

112 ment of exponentially growing cells with the protein synthesis inhibitor cycloheximide (CHX) confirms

113 The ability of the protein synthesis inhibitor cycloheximide (CHX) to preve

114 thesis, the authors gave spinalized rats the protein synthesis inhibitor Cycloheximide (CXM) or salin

115 Treatment of TM cells with the protein synthesis inhibitor cycloheximide abolished the

116 Administration of the protein synthesis inhibitor cycloheximide after training

117 The protein synthesis inhibitor cycloheximide also has a cyt

118 Both the protein synthesis inhibitor cycloheximide and cyclin E a

119 The protein synthesis inhibitor cycloheximide and the protea

120 y ER-E2F1 occurs even in the presence of the protein synthesis inhibitor cycloheximide and thus appea

121 f HMGI-C mRNA level is sensitive to both the protein synthesis inhibitor cycloheximide and transcript

122 Pretreatment with protein synthesis inhibitor cycloheximide antagonized BB

123 induced by 1S,3R-ACPD was attenuated by the protein synthesis inhibitor cycloheximide as well as by

124 te early gene, pretreatment of mice with the protein synthesis inhibitor cycloheximide before either

125 NA synthesis inhibitor actinomycin D and the protein synthesis inhibitor cycloheximide both completel

126 thesis of this transcript was blocked by the protein synthesis inhibitor cycloheximide but not by the

127 stigated whether induction of c-Myc by OA or protein synthesis inhibitor cycloheximide contributed to

128 The protein synthesis inhibitor cycloheximide decreased GnRH

129 The eukaryotic protein synthesis inhibitor cycloheximide did not block

130 Whereas the protein synthesis inhibitor cycloheximide did not block

131 Because the protein synthesis inhibitor cycloheximide did not preven

132 n of STAT6, and is blocked by the reversible protein synthesis inhibitor cycloheximide during the IL-

133 onfluent OCCM cells were pretreated with the protein synthesis inhibitor cycloheximide followed by fl

134 must be maintained by recycling, because the protein synthesis inhibitor cycloheximide has no effect

135 Slowing the translation rate with the protein synthesis inhibitor cycloheximide increased the

136 bitors SB202190 and SB203580 and the general protein synthesis inhibitor cycloheximide inhibited both

137 ylation and that treatment of cells with the protein synthesis inhibitor cycloheximide led to an almo

138 The protein synthesis inhibitor cycloheximide markedly (P<.0

139 increase in CCL20 levels was not affected by protein synthesis inhibitor cycloheximide nor protein tr

140 r in vivo intravitreal administration of the protein synthesis inhibitor cycloheximide or lactacystin

141 Treatment with the protein synthesis inhibitor cycloheximide or RNA interfe

142 is increased by co-treatment with either the protein synthesis inhibitor cycloheximide or the phospha

143 The protein synthesis inhibitor cycloheximide potentiated EM

144 Pretreating the animals with protein synthesis inhibitor cycloheximide prevented I/R-

145 in thyroid cells, whereas treatment with the protein synthesis inhibitor cycloheximide prior to Fas a

146 Experiments performed with the protein synthesis inhibitor cycloheximide provided evide

147 Kinetic studies using the protein synthesis inhibitor cycloheximide showed that TR

148 The protein synthesis inhibitor cycloheximide significantly

149 ections of mGluR1 antagonist JNJ16259685 and protein synthesis inhibitor cycloheximide significantly

150 eins after UV exposure or treatment with the protein synthesis inhibitor cycloheximide were similar.

151 cular and intrahippocampal injections of the protein synthesis inhibitor cycloheximide, administered

152 e cultured in the presence or absence of the protein synthesis inhibitor cycloheximide, and prorenin

153 cluding the immunosuppressant rapamycin, the protein synthesis inhibitor cycloheximide, and several p

154 SA was potent, rapid, and insensitive to the protein synthesis inhibitor cycloheximide, and we conclu

155 ightfold within 6 h after treatment with the protein synthesis inhibitor cycloheximide, but simultane

156 is when administered in combination with the protein synthesis inhibitor cycloheximide, but the apopt

157 atory O2 uptake by SA was insensitive to the protein synthesis inhibitor cycloheximide, but was subst

158 gulate CXCR4 expression was abrogated by the protein synthesis inhibitor cycloheximide, clearly indic

159 oproteins by responders was resistant to the protein synthesis inhibitor cycloheximide, coincided wit

160 FQR1 mRNA abundance is not diminished by the protein synthesis inhibitor cycloheximide, demonstrating

161 ol receptor cell line in the presence of the protein synthesis inhibitor cycloheximide, indicating th

162 In the presence of the protein synthesis inhibitor cycloheximide, LPS primarily

163 Sensitivity of the MDR RV+ cells to the protein synthesis inhibitor cycloheximide, saponin, and

164 In the presence of de novo protein synthesis inhibitor cycloheximide, SGN-40 signif

165 DR) action, and can occur in the presence of protein synthesis inhibitor cycloheximide, showing that

166 nscription is induced in the presence of the protein synthesis inhibitor cycloheximide, so it appears

167 d apoptosis did occur in the presence of the protein synthesis inhibitor cycloheximide, suggesting th

168 affected keratinocytes were treated with the protein synthesis inhibitor cycloheximide, the steady-st

169 s also abrogated in vitro and in vivo by the protein synthesis inhibitor cycloheximide, validating Te

170 Using the protein synthesis inhibitor cycloheximide, we investigat

171 ver of FOXM1 in MCF-7 cells treated with the protein synthesis inhibitor cycloheximide, whereas overe

172 Finally, the protein synthesis inhibitor cycloheximide, which complet

173 ent fibroblasts, even in the presence of the protein synthesis inhibitor cycloheximide, while Ski is

174 TNF-alpha expression in the presence of the protein synthesis inhibitor cycloheximide.

175 y H2O2 and the induction is sensitive to the protein synthesis inhibitor cycloheximide.

176 tein Bax, a result that was prevented by the protein synthesis inhibitor cycloheximide.

177 is ineffective unless in the presence of the protein synthesis inhibitor cycloheximide.

178 n by "superinduction" in the presence of the protein synthesis inhibitor cycloheximide.

179 a reappearance was completely blocked by the protein synthesis inhibitor cycloheximide.

180 c bcl-2 family member bax or addition of the protein synthesis inhibitor cycloheximide.

181 aspartate receptor antagonist MK-801 and the protein synthesis inhibitor cycloheximide.

182 coid dexamethasone and were augmented by the protein synthesis inhibitor cycloheximide.

183 pplied to cells, even in the presence of the protein synthesis inhibitor cycloheximide.

184 nt in the absence but not in the presence of protein synthesis inhibitor cycloheximide.

185 Using the protein synthesis inhibitors cycloheximide and anisomyci

186 Here, we show that the application of protein synthesis inhibitors cycloheximide and emetine t

187 ment for at least 12 h and is blocked by the protein synthesis inhibitors cycloheximide and puromycin

188 The protein synthesis inhibitors cycloheximide and puromycin

189 The protein synthesis inhibitors cycloheximide and puromycin

190 incorporation was blocked completely by the protein synthesis inhibitors cycloheximide and puromycin

191 On the contrary, treatment with the protein synthesis inhibitors cycloheximide, anisomycin,

192 induced by TNF- alpha in the presence of the protein-synthesis inhibitor cycloheximide.

193 ynthesis as shown by cell treatment with the protein-synthesis inhibitor cycloheximide.

194 Exploration of the effects of other protein synthesis inhibitors (cycloheximide, anisomycin)

195 Pretreatment with the protein synthesis inhibitor, cycloheximide (CHX, 100 mic

196 Prior treatment of rats with the protein synthesis inhibitor, cycloheximide, also blunted

197 Interestingly, the protein synthesis inhibitor, cycloheximide, and protein

198 ective effect was abolished by injecting the protein synthesis inhibitor, cycloheximide, and the affe

199 The protein synthesis inhibitor, cycloheximide, blocked the

200 hronic administration of anti-rat p75 or the protein synthesis inhibitor, cycloheximide, but not anti

201 obility shift of p66shc was inhibited by the protein synthesis inhibitor, cycloheximide, but not by t

202 The eukaryotic protein synthesis inhibitor, cycloheximide, caused a >50

203 Rats received a BLA infusion of the protein synthesis inhibitor, cycloheximide, immediately

204 nd the Notch pathway, or by treatment with a protein synthesis inhibitor, cycloheximide, leads to the

205 ed to apoptosis either by cotreatment with a protein synthesis inhibitor, cycloheximide, or Smac mime

206 s new protein synthesis, as treatment with a protein synthesis inhibitor, cycloheximide, partially re

207 In the presence of a protein synthesis inhibitor, cycloheximide, tumor necros

208 synthesis inhibitor, actinomycin-D, and the protein synthesis inhibitor, cycloheximide, were examine

209 in response to mechanical agitation and the protein synthesis inhibitor, cycloheximide.

210 ase in Ivr2 transcripts was sensitive to the protein synthesis inhibitor, cycloheximide.

211 rown in low concentrations of the eukaryotic protein synthesis inhibitor, cycloheximide.

212 eath in DIV 7-8 neurons was prevented by the protein-synthesis inhibitor, cycloheximide.

213 478, and re-expression was prohibited by the protein synthesis inhibitor cylcoheximide; the lysosome

214 Protein synthesis inhibitors did not prevent Theta Bust

215 e prolonged 1-Hz stimulus in the presence of protein synthesis inhibitors each can be transformed int

216 Additionally, pretreatment with the protein synthesis inhibitor emetine (1 microM) totally p

217 Bath application of the protein synthesis inhibitor emetine or cycloheximide 1 h

218 amtide-2-related inhibitory peptide, and the protein synthesis inhibitors emetine and anisomycin.

219 influx (diazoxide or nimodipine), whereas a protein synthesis inhibitor (emetine) decreased it by on

220 otonin receptor antagonist (methysergide) or protein synthesis inhibitors (emetine or cycloheximide)

221 on develops slowly and may be treatable with protein synthesis inhibitors, even when treatment is del

222 imals that were injected previously with the protein synthesis inhibitor exhibited significantly less

223 al prevented the memory-impairing effects of protein synthesis inhibitors following retrieval.

224 lipid moieties in the presence or absence of protein synthesis inhibitors had no effect on epithelial

225 tent with this idea was the finding that the protein synthesis inhibitors had no measurable effect on

226 ffects that cell-wall active antibiotics and protein-synthesis inhibitors have on transcription and t

227 RA's effect was blocked by either RNA or protein synthesis inhibitors; however, hCAR mRNA's stabi

228 ctrotransformation before selection with the protein synthesis inhibitor hygromycin B was imposed.

229 ection is sensitive to transcription but not protein synthesis inhibitors, implicating a pretranslati

230 ere we show that anisomycin, a commonly used protein synthesis inhibitor in memory research, impairs

231 lation from non-AUG start codons responds to protein synthesis inhibitors in human cells.

232 Thus, the effect of protein synthesis inhibitors in stabilizing the GPI-PLC

233 cells, and the effect of transcriptional and protein synthesis inhibitors indicates de novo IL-10 pro

234 till initiates when embryos are treated with protein synthesis inhibitors, indicating that it is medi

235 STM for FC can occur even in the presence of protein synthesis inhibitors, indicating that redistribu

236 properties are lacking in engram cells under protein synthesis inhibitor-induced amnesia, direct opto

237 In addition, cycloheximide (10 microM), a protein synthesis inhibitor, inhibited the effect of str

238 This OM effect was not blocked by protein synthesis inhibitors, inhibitors of p38 kinase,

239 yos or embryos arrested in interphase with a protein synthesis inhibitor, injection of CycB accelerat

240 Finally, injection of a protein synthesis inhibitor into either ilPFC or CeA imp

241 s preceded by bilateral microinjections of a protein synthesis inhibitor into the basolateral amygdal

242 Postsession infusion of a protein synthesis inhibitor into the prelimbic cortex di

243 Although injecting the protein-synthesis inhibitor into the dorsal hippocampus

244 trast, bilateral injections of anisomycin, a protein synthesis inhibitor, into BLA did not impair the

245 f rats received 0.4 mg/kg cycloheximide, the protein synthesis inhibitor, intraperitoneally before pr

246 method, we use drug combinations comprising protein synthesis inhibitors (macrolides, aminoglycoside

247 However, protein synthesis inhibitors may have additional detrime

248 ed by nifedipine was not prevented by RNA or protein synthesis inhibitors, nor by the caspase inhibit

249 tro, but little is known about the effect of protein synthesis inhibitors on either induction or main

250 Furthermore, incubation with a protein synthesis inhibitor or an NMDAR-antagonist impai

251 Treatment with protein synthesis inhibitors or the expression of the do

252 The DNA degradation was insensitive to protein synthesis inhibitors or UV inactivation of virus

253 Anisomycin (protein synthesis inhibitor) or KT5720 (protein kinase A

254 ately by intra-LA infusions of anisomycin (a protein synthesis inhibitor) or Rp-cAMPS (an inhibitor o

255 session, either a solution of anisomycin (a protein synthesis inhibitor) or vehicle was bilaterally

256 ed Sar1p mutant protein in the presence of a protein synthesis inhibitor, or by plasmid-encoded expre

257 cells, the addition of either anisomycin, a protein synthesis inhibitor, or geranylgeraniol, an inte

258 With protein synthesis inhibitors, phrenic LTF differed from

259 tibiotic spectinomycin is a potent bacterial protein synthesis inhibitor, poor antimycobacterial acti

260 -such that when presented in the presence of protein synthesis inhibitors produce a rapid reversal of

261 cium chelation and by preincubation with the protein synthesis inhibitor puromycin.

262 Incubation with the protein synthesis inhibitor rapamycin during the second

263 tivation was followed by incubation with the protein synthesis inhibitor rapamycin.

264 Infusion of protein synthesis inhibitors (rapamycin or anisomycin) i

265 ent of resistant cells with cycloheximide (a protein synthesis inhibitor) rendered cells sensitive to

266 ing culture of VZ cells in the presence of a protein synthesis inhibitor results after 20 h in a loss

267 cell line by treatment with cycloheximide, a protein synthesis inhibitor, showing that the level of A

268 Here we show that YoeB, a highly potent protein synthesis inhibitor, specifically blocks transla

269 further experiments demonstrated that these protein synthesis inhibitors stimulated rapid and differ

270 Finally, the protein synthesis inhibitors Stx1 and anisomycin trigger

271 Amnesia produced by protein synthesis inhibitors such as anisomycin provides

272 This view stems from the observation that protein synthesis inhibitors, such as anisomycin (ANI),

273 but does not affect sensitivity toward other protein synthesis inhibitors, such as saporin or cyclohe

274 The use of protein synthesis inhibitors suggested that newly synthe

275 al inhibitor) as well as by cycloheximide (a protein synthesis inhibitor), suggesting the involvement

276 , and reductions in mRNA were prevented by a protein synthesis inhibitor, suggesting that GCs suppres

277 anscriptional levels and was unaffected by a protein synthesis inhibitor, suggesting that this did no

278 e transcriptional level and was sensitive to protein synthesis inhibitors, suggesting a requirement f

279 ion in Fragile X mutants could be rescued by protein synthesis inhibitors, suggesting that excess bas

280 Harringtonine, a structurally unrelated protein synthesis inhibitor that competes with trichothe

281 Omacetaxine mepesuccinate is a protein synthesis inhibitor that has demonstrated activi

282 deoxyadenosine (cladribine) and puromycin, a protein synthesis inhibitor that is often used as a domi

283 Rocaglamide A (RocA) typifies a class of protein synthesis inhibitors that selectively kill aneup

284 Streptogramins A is a class of protein synthesis inhibitors that target the peptidyl tr

285 erience and shortly afterward treated with a protein synthesis inhibitor, the consolidated memory for

286 We found that the addition of protein synthesis inhibitors to acute slices (in which s

287 be restored by the selective application of protein synthesis inhibitors to distal axons.

288 strategy in KSHV-infected cells treated with protein synthesis inhibitors to identify direct transcri

289 Addition of protein synthesis inhibitors to TRAIL-resistant melanoma

290 Furthermore, our data show that the protein synthesis inhibitors used previously to test the

291 e inclusion by incubation in the presence of protein synthesis inhibitors, vesicles containing elemen

292 f conditioned responses, indicating that the protein synthesis inhibitor was applied to the eyeblink-

293 It was prevented when cycloheximide, a protein synthesis inhibitor, was added up to 6 hr after

294 Using protein synthesis inhibitors we showed that the degradat

295 When protein synthesis inhibitors were added 15 min before ad

296 indicated that the new macrolides are potent protein synthesis inhibitors, which interact with methyl

297 yed increase in synaptotagmin was blocked by protein synthesis inhibitors, while the early increase i

298 atives, even though such efforts may lead to protein synthesis inhibitors with improved or alternate

299 hypotheses that delayed administration of a protein synthesis inhibitor would be effective in reduci

300 ypothesized that the use of a bacteriostatic protein synthesis inhibitor would improve outcomes by re